Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn’s Disease With up to 6 Years of Follow-Up in the Pyramid Registry.

Related Articles Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn’s Disease With up to 6 Years of Follow-Up in the Pyramid Registry. Am J Gastroenterol. 2018 Jun 05;: Authors: D’Haens G, Reinisch W, Panaccione R, Satsangi J, Petersson J, Bereswill M, Arikan D, Perotti E, Robinson AM, Kalabic J, Alperovich G, Thakkar R, Loftus EV Abstract OBJECTIVES: Real-world, prospective, long-term studies in Crohn’s disease (CD) characterizing adalimumab safety data and lymphoma risk were lacking. We present the final results from the PYRAMID registry, which was designed…

Read More

Tumor Necrosis Factor Ligand-Related Molecule 1A Regulates the Occurrence of Colitis-Associated Colorectal Cancer.

Related Articles Tumor Necrosis Factor Ligand-Related Molecule 1A Regulates the Occurrence of Colitis-Associated Colorectal Cancer. Dig Dis Sci. 2018 May 24;: Authors: Niu W, Wu Z, Wang J, Zhang H, Jia W, Yang M, Luo Y, Zhang X Abstract BACKGROUND: Tumor necrosis factor ligand-related molecule 1 A (TLlA) is closely related to the occurrence and development of inflammatory bowel disease. AIMS: We aimed to explore whether TLlA was involved in the occurrence of colitis-associated colorectal cancer (CAC). METHODS: Firstly, azoxymethane (AOM) and dextran sulfate sodium (DSS) were used to construct…

Read More

Analysis of DNA Methylation at Specific Loci in Stool Samples Detects Colorectal Cancer and High-grade Dysplasia in Patients with Inflammatory Bowel Disease.

Analysis of DNA Methylation at Specific Loci in Stool Samples Detects Colorectal Cancer and High-grade Dysplasia in Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2018 May 15;: Authors: Kisiel JB, Klepp P, Allawi HT, Taylor WR, Giakoumopoulos M, Sander T, Yab TC, Moum BA, Lidgard GP, Brackmann S, Mahoney DW, Roseth A, Ahlquist DA Abstract BACKGROUND & AIMS: Patients with inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), are at increased risk for colorectal cancer (CRC). Analyses of DNA methylation patterns in stool samples have…

Read More

Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis.

Related Articles Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis. J Crohns Colitis. 2018 May 12;: Authors: Yang C, Huang J, Huang X, Huang S, Cheng J, Liao W, Chen X, Wang X, Dai S Abstract Background and Aims: The association between anti-tumor necrosis factor alpha agents and the risk of lymphoma in patients with inflammatory bowel disease has already been sufficiently reported. However, the results of these studies are inconsistent. Hence, this analysis was conducted to…

Read More

Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients.

Related Articles Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. Dig Dis Sci. 2018 Apr 30;: Authors: Anderson A, Ferris LK, Click B, Ramos-Rivers C, Koutroubakis IE, Hashash JG, Dunn M, Barrie A, Schwartz M, Regueiro M, Binion DG Abstract BACKGROUND: Dermatologic manifestations of inflammatory bowel disease (IBD) are common, and certain IBD medications increase the risk of skin cancer. AIMS: To define the rates of care and factors associated with dermatologic utilization with a focus on skin cancer screening. METHODS: We utilized a…

Read More

Low Incidence of Dysplasia and Colorectal Cancer Observed among Inflammatory Bowel Disease Patients with Prolonged Colonic Diversion.

Related Articles Low Incidence of Dysplasia and Colorectal Cancer Observed among Inflammatory Bowel Disease Patients with Prolonged Colonic Diversion. Inflamm Bowel Dis. 2018 Apr 23;24(5):1092-1098 Authors: Bettner W, Rizzo A, Brant S, Dudley-Brown S, Efron J, Fang S, Gearhart S, Marohn M, Parian A, Kherad Pezhouh M, Melia J, Safar B, Truta B, Wick E, Lazarev M Abstract Background: In inflammatory bowel disease (IBD), many scenarios call for fecal diversion, leaving behind defunctionalized bowel. The theoretical risk of colorectal cancer (CRC) in this segment is frequently cited as a reason…

Read More

Cancer-Associated Chemotherapy Induces Less IBD Exacerbations and a Reduction of IBD Medication Afterwards.

Cancer-Associated Chemotherapy Induces Less IBD Exacerbations and a Reduction of IBD Medication Afterwards. Inflamm Bowel Dis. 2018 Apr 13;: Authors: Koc ÖM, van Kampen RJW, van Bodegraven AA Abstract Background: The prevalence of inflammatory bowel disease (IBD) is increasing and, consequently, more IBD patients will develop cancer with need for cancer-associated chemotherapy. Physicians are therefore confronted with whether they should continue, stop, or restart IBD medication in relation with chemotherapy. The current strategy in our hospital is to discontinue immunomodulating IBD medication, comprising corticosteroids, anti-tumour necrosis factor (anti-TNF), and other…

Read More

Incidence and classification of postcolonoscopy colorectal cancers in inflammatory bowel disease: A Dutch population-based cohort study.

Incidence and classification of postcolonoscopy colorectal cancers in inflammatory bowel disease: A Dutch population-based cohort study. J Crohns Colitis. 2018 Apr 10;: Authors: Wintjens DSJ, Bogie RMM, van den Heuvel TRA, le Clercq CMC, Oostenbrug LE, Romberg-Camps MJL, Straathof JW, Stassen LPS, Masclee AAM, Jonkers DMAE, Sanduleanu-Dascalescu S, Pierik MJ Abstract Background and Aims: Patients with inflammatory bowel disease (IBD) colitis are at increased risk for colorectal cancer (CRC). We examined the proportion and most likely aetiology of potentially preventable postcolonoscopy CRCs (PCCRCs) in a population-based cohort. Furthermore, adherence to…

Read More
<< Go Back